Ryo Yanai

Ryo Yanai

Auto-generated profile, based on publicly available information

Ryo Yanai

Division of Rheumatology, Department of Medicine Showa Medical University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
YKYu Katayama
Yu Katayama
RYRyo Yanai
Ryo Yanai
TITakahiro Itaya
Takahiro Itaya
YNYusuke Nagamine
Yusuke Nagamine
KTKyosuke Tanigawa
Kyosuke Tanigawa
YMYoshia Miyawaki
Yoshia Miyawaki

22 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DWDaisuke Waki
Daisuke Waki
HTHiroya Tamai
Hiroya Tamai
RYRitsuko Yokochi
Ritsuko Yokochi
TKToshiki Kido
Toshiki Kido
YYYuriko Yagyu
Yuriko Yagyu
KSKen-Ei Sada
Ken-Ei Sada
Comparison of clinical response to methotrexate between anti-SSA antibody-positive and -negative patients with methotrexate-naïve rheumatoid arthritis and investigate the reasons for the differences in the response. For this multicenter retrospective cohort study, a total of 210 consecutive patients with rheumatoid arthritis who newly initiated methotrexate were recruited. The effects of anti-SSA antibody positivity on achieving a low disease activity according to the 28-joint Disease Activity Score based on C-reactive protein after 6 months of methotrexate administration were investigated using a logistic regression analysis. This study involved 32 and 178 anti-SSA antibody-positive and -negative patients, respectively. The rate of achieving low disease activity according to the 28-joint Disease Activity Score based on C-reactive protein at 6 months was significantly lower in the anti-SSA antibody-positive group than in the anti-SSA antibody-negative group (56.2% vs. 75.8%, P = 0.030). After 6 months, anti-SSA antibody-positive patients had significantly higher scores on the visual analogue scale (median [interquartile range]: 22 [15–41] vs. 19 [5–30], P = 0.038) and were frequently prescribed nonsteroidal anti-inflammatory drugs (37.5% vs. 18.0%, P = 0.018). In conclusion, the presence of anti-SSA antibodies might be a predictive factor for insufficient responses to treat-to-target strategy in rheumatoid arthritis. Residual pain might contribute to the reduced clinical response to methotrexate in anti-SSA antibody-positive patients with rheumatoid arthritis.

29 August 2025 in Modern Rheumatology
Verified
Journal Article
Closed access
TMToshihiro Matsui
Toshihiro Matsui
MFMie Fusama
Mie Fusama
KKKimito Kawahata
Kimito Kawahata
RSRyoko Sakai
Ryoko Sakai
TSTakahiko Sugihara
Takahiko Sugihara
YKYutaka Kawahito
Yutaka Kawahito
Objectives: This study aimed to evaluate the knowledge, experience, and challenges faced by care and welfare professionals in supporting patients with rheumatoid arthritis (RA) in Japan, and to identify issues related to coordination between medical and welfare services. Methods: A nationwide questionnaire survey was conducted using stratified regional sampling. The target population included 1000 members each from the Japan Care Manager Association (JCMA) and the Japanese Association of Certified Social Workers (JASW). The survey assessed respondents’ knowledge of RA, support experience, actual practices, views on interdisciplinary collaboration, and perceptions of patients’ understanding of available systems. Results: Valid responses were obtained from 390 JCMA members and 330 JASW members. While basic knowledge of RA symptoms and disease course was common, awareness of RA-specific medications was limited, especially among JASW respondents. Many participants had little experience supporting RA patients. The reported challenges included insufficient information from physicians, a lack of structured information sharing, and underestimation of care needs in long-term care certification. Patients and families also showed limited understanding of healthcare and welfare systems. Conclusions: The findings highlight the need for improved education, better interdisciplinary coordination, and enhanced information sharing. Comprehensive efforts are essential to ensure continuous, high-quality care for RA patients in community settings.

6 January 2026 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
KSKen-Ei Sada
Ken-Ei Sada
YMYoshia Miyawaki
Yoshia Miyawaki
RYRyo Yanai
Ryo Yanai
TKTakashi Kida
Takashi Kida
AOAkira Onishi
Akira Onishi
YSYasuhiro Shimojima
Yasuhiro Shimojima

1 April 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
RYRyo Yanai
Ryo Yanai
YIYuzo Ikari
Yuzo Ikari
YMYuta Michizu
Yuta Michizu
NYNobuyuki Yajima
Nobuyuki Yajima

4 November 2025 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
SFS Fukui
S Fukui
Kunihiro IchinoseKunihiro Ichinose
Kunihiro Ichinose
HIH Ide
H Ide
TUT Uchida
T Uchida
STShimizu, Toshimasa
Shimizu, Toshimasa
AKA Kawakami
A Kawakami
To evaluate the relationship between anti-neutrophil cytoplasmic antibody (ANCA) positivity and the disease characteristics, treatment, and prognosis of eosinophilic granulomatosis with polyangiitis (EGPA). We conducted a retrospective cohort study of patients with new-onset or severely relapsing ANCA-associated vasculitis, enrolled in the J-CANVAS registry. The clinical characteristics at baseline, treatments, and prognoses of ANCA-positive and ANCA-negative patients were assessed. Three patients with positive proteinase-3 ANCA were excluded, and 166 patients with EGPA (new onset, 159; severe relapse, seven) were included. Sixty-two patients were myeloperoxidase (MPO)-ANCA positive and 104 patients were negative. No differences in age or sex were observed between the two groups. The MPO-ANCA-positive group had significantly more frequent mucous membrane and eye involvement, more frequent renal involvement, higher total Birmingham Vasculitis Activity Score, higher neutrophil counts, and higher C-reactive protein levels at baseline. Although rituximab was administered more frequently in the MPO-ANCA-positive group, no other differences in treatment were found. Both groups had comparable estimated glomerular filtration rates and prednisolone doses at weeks 24 and 48. The incidence rates of severe relapse, minor relapse, and serious infectious diseases were comparable. Cox regression analysis revealed that MPO-ANCA positivity was not a significant factor in serious infectious diseases and relapse. Patients with MPO-ANCA-positive EGPA demonstrated different baseline clinical characteristics from MPO-ANCA-negative patients. However, subsequent relapses and serious infectious diseases were comparable.